Format

Send to

Choose Destination
Ment Health Clin. 2018 Nov 1;8(6):294-302. doi: 10.9740/mhc.2018.11.294. eCollection 2018 Nov.

The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review.

Author information

1
PGY-1 Pharmacy Practice Resident, William Jennings Bryan Dorn VA Medical Center, Columbia, South Carolina.
2
(Corresponding author) Associate Professor of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, South Carolina; Clinical Psychiatric Pharmacist, Division of Inpatient Services, G. Werber Bryan Psychiatric Hospital, Columbia, South Carolina, etill2020@gmail.com.

Abstract

Introduction:

Pharmacogenetic testing may assist in identifying an individual's risk of developing a mental illness as well as predict an individual's response to treatment. The objective of this study is to report published outcomes of pharmacogenetic testing in patients with schizophrenia or bipolar disorder.

Methods:

A systematic review using PubMed and EBSCOhost through April 2017 was performed to identify articles that reported pharmacogenetic testing in adult patients with either bipolar disorder or schizophrenia using the keywords pharmacy, pharmacogenomics, pharmacogenetics, psychiatry, bipolar disorder, schizophrenia, mood stabilizer, and antipsychotic.

Results:

A total of 18 articles were included in the final literature review. A wide variety of genes amongst adult patients with varying ethnicities were found to be correlated with the development of schizophrenia or bipolar disorder as well as response to antipsychotics and mood stabilizers.

Discussion:

While current studies show a correlation between genetic variations and medication response or disease predisposition for patients with schizophrenia and bipolar disorder, research is unclear on the type of therapeutic recommendations that should occur based on the results of the pharmacogenetic testing. Hopefully interpreting pharmacogenetic results will one day assist with optimizing medication recommendations for individuals with schizophrenia and bipolar disorder.

KEYWORDS:

antipsychotic; bipolar disorder; mood stabilizer; pharmacogenetics; pharmacogenomics; pharmacy; psychiatry; schizophrenia

Conflict of interest statement

Disclosures: M.R. and J.K. were pharmacy students in the Class of 2018 at Presbyterian College School of Pharmacy in Clinton, South Carolina at the time of writing this manuscript. The authors certify that they have no affiliations or involvement with any financial or nonfinancial interest in the subject matter or materials discussed in this manuscript.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center